Sex and Gender Differences in Diabetes Risk

Older man taking pills at a table while woman reads instructions — Photo: Ground Picture / Shutterstock

Type 2 diabetes hits men and women on different timelines, with different warning signs, and with very different stakes for the heart.

Quick Take

Men typically get diagnosed with type 2 diabetes younger and at lower body weight than women.
Women usually carry more risk factors, especially obesity, by the time doctors catch the disease.
Once diagnosed, women face a much steeper jump in heart disease and death risk compared to men.
Large trials show women and men respond differently to treatment, yet care often ignores that gap.

Diagnosis Age And Body Weight Split Sharply By Sex

Doctors have long noticed a pattern in their exam rooms. Men tend to show up with type 2 diabetes earlier in life and while carrying less body fat than women. A major 2023 review confirmed this, stating plainly that men are “usually diagnosed at a younger age and lower body fat mass than women”. That gap shapes how each sex experiences the disease from day one.

Women, by contrast, often carry a heavier load of risk factors before diagnosis even happens. The same research found women “bear a greater risk factor burden,” with obesity leading the list. That means by the time many women get their diagnosis, more damage may already be building quietly inside their bodies.

Global Numbers Flip Depending On Age And Life Stage

Zoom out to the whole planet, and the picture gets more complicated. One review found an estimated 17.7 million more men than women live with diabetes worldwide. But that gap is not fixed. More boys develop it before puberty, and more women develop it after menopause and in older age, showing the disease shifts its target across a lifetime.

This age-based flip matters for anyone assuming diabetes looks the same at every stage of life. A woman in her thirties faces a different risk landscape than a woman in her sixties. Policymakers and doctors setting screening rules need to account for that shifting target instead of using one blanket age cutoff for everyone.

Women Pay A Steeper Price In Heart Disease And Death

The starkest difference shows up after diagnosis, in the heart. A 2019 review found type 2 diabetes drives a “25-50% greater excess risk” of a cardiovascular event in women compared with men carrying the same disease. That is not a small gap. It means diabetes erases more of women’s natural cardiovascular protection than it does for men.

A separate meta-analysis backed this up with hard numbers. Researchers calculated death risk ratios of 2.33 for women with diabetes versus healthy peers, compared to 1.91 for men. They concluded the disease’s damage runs roughly 17 percent higher for all-cause death and 97 percent higher for heart disease death in women than in men. That second figure alone should reshape how seriously women’s diabetes symptoms get treated.

Clinical Trials Reveal Uneven Treatment And Outcomes

Large drug trials add another layer. In the TECOS trial, the main combined health outcome hit 9.7 percent of women compared with 12.3 percent of men, and women also had lower rates of cardiovascular and overall death. On paper, that sounds like better news for women, but researchers caution these raw numbers don’t capture the full relative risk story tied to diabetes itself.

The EXSCEL trial found something troubling underneath those numbers. Women entered the study with “a less favourable metabolic risk profile and lower use of cardioprotective medications,” yet still posted lower rates of major cardiac events than men. That combination suggests women may be under-treated with heart-protective drugs even while starting from a worse metabolic position, a gap doctors should be closing, not tolerating.

Why This Difference Deserves More Attention, Not Less

A 2023 synthesis argues the evidence already justifies rethinking screening and treatment by sex, since women were diagnosed about three years later on average, with higher body weight but lower blood sugar readings at diagnosis. That timing gap could mean current screening thresholds miss early warning signs in women simply because doctors are looking for the male pattern first.

None of this proves one sex has it “worse” across the board, since relative risk and absolute event counts don’t always move together. But the pattern is consistent enough across multiple large studies to matter. Patients, especially women managing weight and blood sugar risk factors, deserve doctors who screen and treat with these documented differences in mind, not a one-size-fits-all approach built around outdated assumptions.